Fig. 4.

CCR4 antagonism significantly reduces BO patient-derived T cell migration to recombinant chemokine cocktail. PBMC from healthy donors (white), BO (grey) and OAC (black) patients were pre-treated with chemokine receptor antagonists for 1 h prior to chemotaxis assay using a transwell system and a cocktail of recombinant chemokines (composed of 10 ng/ml each of IP-10 (CXCL10), MIP-1α (CCL3), MIP-3α (CCL20), RANTES (CCL5) and TARC (CCL17) were placed in the bottom chamber and allowed to migrate for 2 h. Bar charts show CD3⁺ (A), CD4⁺ (B) and CD8⁺ (C) T cell migration expressed as a percentage of migrated cells to media only control (set to 100%). All data is presented as mean ± SEM, n = 3. Paired t test was carried out between treatments (between --, − + and ++ bars of same colour), unpaired t test was carried out between disease stages. *p ≤ 0.05